Business Context and Reporting Period
iBio, Inc., a Delaware corporation, filed this Form 8-K on November 29, 2017, to report the entry into a Material Definitive Agreement. The filing details an underwriting agreement with Aegis Capital Corp. for a public offering of common stock, with the transaction expected to close on or about November 30, 2017.
Key Financial Metrics and Transaction Details
- Shares Issued: 22,500,000 shares of Common Stock.
- Public Offering Price: $0.20 per share.
- Expected Net Proceeds: Approximately $4,180,000 (after deducting underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: The Underwriter has a 45-day option to purchase up to an additional 3,375,000 shares.
- Underwriting Discounts: 7% of the public offering price for general investors; 3.5% for certain investors with pre-existing relationships.
- Additional Compensation: The Company agreed to issue the Underwriter shares equal to 2% of the aggregate shares sold (excluding shares sold to certain pre-existing investors).
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company.
Material Changes and Lock-Up Provisions
The primary material change is the dilution of existing shareholders due to the issuance of new shares. Pursuant to the Underwriting Agreement, the Company, its officers, directors, and certain key shareholders have agreed to a lock-up period ending 90 days after the date of the agreement. During this period, they may not sell or dispose of any Common Stock without the written consent of the Underwriter, subject to certain exceptions.
Outlook, Risks, and Management Commentary
The Company intends to use the net proceeds from the offering, though the specific allocation of funds is not detailed in this text. The offering is subject to customary closing conditions. The filing notes that the Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions. The description of terms in this report is qualified in its entirety by reference to the full Underwriting Agreement filed as Exhibit 1.1.
Key Facts for Investor Verification
- Verify the final closing date and whether the over-allotment option was exercised.
- Confirm the exact net proceeds received after all expenses, as the $4,180,000 figure is an estimate.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification liabilities and termination clauses.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.
- Check subsequent filings for the specific intended use of the raised capital.